cellvie

Executive Summary

cellvie is a Swiss biotechnology company pioneering Therapeutic Mitochondria Transplantation (TMT), a novel modality that restores cellular energy metabolism by transplanting functional mitochondria into compromised cells. Founded in 2017 and based in Zurich, the company initially targets ischemia-reperfusion injury (IRI) in kidney transplantation, a condition with high unmet need where mitochondrial dysfunction drives organ damage and rejection. cellvie's approach aims to mitigate IRI by providing a bolus of healthy mitochondria during organ preservation, potentially improving graft function and patient outcomes. The technology is platform-based, with applicability beyond kidney transplantation to other ischemic injuries and mitochondrial diseases. The company is at a preclinical stage, with research published in peer-reviewed journals. While TMT is a highly innovative and disruptive concept, it faces significant scientific, manufacturing, and regulatory challenges, including scale-up of mitochondrial isolation and delivery, immune compatibility, and demonstration of efficacy in large animal models prior to clinical trials. The company has not disclosed funding rounds or valuation, indicating it may be in early development or operating with non-dilutive grants. Overall, cellvie represents a high-risk, high-reward opportunity in the biologics space, with potential to transform transplant medicine and beyond if technical hurdles are overcome.

Upcoming Catalysts (preview)

• H2 2026Preclinical proof-of-concept data in large animal models45% success
• 2026Series A financing round or grant award50% success
• 2027IND/CTA filing for first-in-human trial in kidney transplantation30% success